Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $132.9 million.

  • Integra Lifesciences Holdings' Accumulated Expenses rose 69.8% to $132.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 69.8%. This contributed to the annual value of $121.9 million for FY2024, which is 2088.77% up from last year.
  • Integra Lifesciences Holdings' Accumulated Expenses amounted to $132.9 million in Q3 2025, which was up 69.8% from $131.4 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year Accumulated Expenses high stood at $137.4 million for Q1 2025, and its period low was $79.0 million during Q3 2022.
  • Its 5-year average for Accumulated Expenses is $106.3 million, with a median of $102.5 million in 2024.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Accumulated Expenses crashed by 3355.94% in 2022, and later surged by 4610.21% in 2024.
  • Over the past 5 years, Integra Lifesciences Holdings' Accumulated Expenses (Quarter) stood at $120.5 million in 2021, then tumbled by 33.56% to $80.0 million in 2022, then rose by 26.0% to $100.8 million in 2023, then rose by 20.89% to $121.9 million in 2024, then rose by 8.98% to $132.9 million in 2025.
  • Its Accumulated Expenses stands at $132.9 million for Q3 2025, versus $131.4 million for Q2 2025 and $137.4 million for Q1 2025.